

Sanofi  
Form 6-K  
January 22, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

---

**For the month of January 2014**

**Commission File Number: 001-31368**

**SANOFI**

(Translation of registrant's name into English)

**54, rue La Boétie, 75008 Paris, FRANCE**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Edgar Filing: Sanofi - Form 6-K

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

## Edgar Filing: Sanofi - Form 6-K

In January 2014, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.3 which are incorporated herein by reference.

### Exhibit List

| <b>Exhibit No.</b> | <b>Description</b>   |
|--------------------|--|
| Exhibit 99.1       | Status of CVR Product Sales Milestone #1 as of January 16, 2014  |
| Exhibit 99.2       | Press release dated January 15, 2014: Sanofi and Fraunhofer-Gesellschaft Announce the Creation of a Natural Product Center of Excellence |
| Exhibit 99.3       | Press release dated January 13, 2014: Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases                                  |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: January 22, 2014

SANOFI

By

/S/ John Felitti

Name:

John Felitti

Title:

Associate Vice President,  
Corporate Law, Financial & Securities  
Law

**Exhibit Index**

| <b>Exhibit No.</b> | <b>Description</b>   |
|--------------------|--|
| Exhibit 99.1       | Status of CVR Product Sales Milestone #1 as of January 16, 2014  |
| Exhibit 99.2       | Press release dated January 15, 2014: Sanofi and Fraunhofer-Gesellschaft Announce the Creation of a Natural Product Center of Excellence |
| Exhibit 99.3       | Press release dated January 13, 2014: Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases                                  |